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contributes to homoeostasis of the microenvironment of the central nervous system and
protection from pathogens and toxins. Key features of the BBB phenotype are presence of
complex intercellular tight junctions giving a high transendothelial electrical resistance
(TEER), and strongly polarised (apical:basal) localisation of transporters and receptors. In
vitro BBB models have been developed from primary culture of brain endothelial cells of
several mammalian species, but most require exposure to astrocytic factors to maintain
the BBB phenotype. Other limitations include complicated procedures for isolation, poor
yield and batch-to-batch variability. Some immortalised brain endothelial cell models have
proved useful for transport studies but most lack certain BBB features and have low TEER.
We have developed an in vitro BBB model using primary cultured porcine brain endothelial
cells (PBECs) which is relatively simple to prepare, robust, and reliably gives high TEER
(mean∼800 Ω cm2); it also shows good functional expression of key tight junction proteins,
transporters, receptors and enzymes. The model can be used either in monoculture, for
studies of molecular ﬂux including permeability screening, or in co-culture with astrocytes
when certain specialised features (e.g. receptor-mediated transcytosis) need to be maxi-
mally expressed. It is also suitable for a range of studies of cell:cell interaction in normal
physiology and in pathology. The method for isolating and growing the PBECs is given in
detail to facilitate adoption of the model.
This article is part of a Special Issue entitled Companion Paper.
& 2013 The Authors. Published by Elsevier B.V. Open access under CC BY license.Elsevier B.V.
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The blood–brain barrier (BBB) is formed by the endothelial cells
of cerebral microvessels under the inﬂuence of associated cells
of the neurovascular unit (NVU), chieﬂy pericytes and the end-
feet of perivascular astrocytes (Abbott et al., 2006; Neuwelt et al.,
2011; Wolburg et al., 2009). The BBB is the protective interface
regulating molecular, ionic and cellular trafﬁc between the blood
and the central nervous system (CNS). The barrier has several
key features (Abbott et al., 2010). The ‘physical barrier’ results
from the nature of the lipid membranes and presence of
particularly tight intercellular zonulae occludentes (tight junctions);
the junctions help to segregate apical and basal membrane
proteins, conferring strong cellular polarity, and signiﬁcantly
restrict permeability of small hydrophilic solutes through the
intercellular cleft (paracellular pathway), giving rise to the high
transendothelial electrical resistance (TEER) (Abbott et al., 2010;
Tsukita et al., 2001; Wolburg et al., 2009). The ‘transport barrier’
applies to transcellular ﬂux of small and large molecules: solute
transporter proteins (SLCs) and ATP-binding cassette (ABC) efﬂux
transporters regulate trafﬁc of small molecules (nutrients, sub-
strates, waste products) (Begley, 2004; Mahringer et al., 2011;
Miller, 2010), while speciﬁc vesicular mechanisms regulate
permeation of peptides and proteins needed by the CNS (Bickel
et al., 2001; Hervé et al., 2008; Jones and Shusta, 2007). The
‘enzymatic’ or ‘metabolic barrier’ function of the BBB results
from the presence of a number of ecto- and endo-enzymes
including cytochrome P450s (CYPs) that add a further level of
protection (Ghosh et al., 2011). Finally the ‘immunological barrier’
restricts and regulates the entry of circulating leucocytes, main-
taining a low level immune surveillance of the CNS, and with the
potential for concerted response in conditions of pathology
(Greenwood et al., 2011; Hawkins and Davis, 2005; Persidsky
et al., 2006; Stanimirovic and Friedman, 2012).
In vivo studies continue to provide valuable information about
the physiology and pathology of the BBB and operation of the
NVU; however, for detailed molecular and functional under-
standing, in vitro models can give particular additional insights
(Deli et al., 2005; Naik and Cucullo, 2012). Moreover, in vitro
models allow rapid conduct of complex experiments involving
parallel manipulation of bathing media, addition of inhibitors
and calculation of transport kinetics while minimising the use of
animals. For studies of transendothelial ﬂux, including drug
permeability assays, it is important to use models with well-
developed tight junctions (high TEER) and well preserved apical:
basal polarity of transporters and receptors (Abbott et al., 2008;
Deli et al., 2005; Tóth et al., 2011).
The key features of the adult BBB result from a sequence of
cell:cell interactions during development between the ingrowing
vessel sprouts and the associated cells of the NVU (Liebner et al.,
2011). When brain microvessels are isolated from adult mam-
malian brain and brain endothelial cells are cultured from these
vessel fragments, they retain many key features of the BBB phe-
notype. In 1969, Siakotos and colleagues described for the ﬁrst
time a method to successfully isolate bovine and human brain
endothelial cells (Siakotos et al., 1969). Nearly a decade later,
Panula et al. demonstrated the migration of rat brain endothelial
cells from isolated capillaries. These cells were able to grow in
culture and had strong alkaline phosphatase activity (Panulaet al., 1978). Tontsch and Bauer (1989) simpliﬁed the culture
methods for isolating murine and porcine brain endothelial cells
(e.g. avoiding sieving steps, gradient centrifugations) and opti-
mised the culture medium to increase cell yield. They also found
that when proliferative factors such as endothelial cell growth
supplement (ECGS) and heparin were removed from culture
medium, themorphology of cells changed from spindle-shape to
cobblestone phenotype. Through a series of experiments,
DeBault and Cancilla gave evidence for the inﬂuence of astro-
cytic factors on BBB phenotype of brain endothelial cells (DeBault
and Cancilla, 1980a, 1980b; DeBault, 1981). These studies led to
the development of co-culture models of the BBB (Joó, 1985).
We chose to develop a porcine BBB model for several
reasons: (1) A single pig brain gives a high yield of cells
compared to that from rat or mouse. (2) Porcine brains are
relatively easy to obtain as they are a by-product of the meat
industry; there is no need to have animal breeding facilities
on site to maintain a continuous supply of brain tissue. (3)
Porcine brain endothelial cells (PBECs) generally retain many
key features of the BBB following isolation, and the rate of
loss of BBB phenotype in culture is less than for rodent or
bovine BBB models (Deli et al., 2005), therefore co-culture
with astrocytes is not essential to induce functional expres-
sion of tight junctions (i.e. high TEER) (Patabendige et al., this
issue). (4) The porcine genome, anatomy, physiology and
disease progression reﬂect human biology more closely than
many established laboratory animals (Walters et al., 2011). (5)
The availability of miniature pigs and novel porcine trans-
genic disease models make the pig the most suitable animal
model to study human disease (Bendixen et al., 2010; Lunney,
2007). The miniature pig is now a well established ‘large’
mammalian model for pharmacokinetics/toxicology studies
(Bode et al., 2010) and is also used for surgical studies
to generate organs for xenotransplantation (Vodicka et al.,
2005). Transgenic pig models have been established for stud-
ying several diseases, including Alzheimer’s disease, Hun-
tington's disease, cardiovascular disease, cystic ﬁbrosis and
diabetes mellitus (Aigner et al., 2010).
We have developed and validated a cell culture model of
the BBB using PBECs with functional tight junctions
(Patabendige et al., this issue). This model reliably gives high
TEER (mean TEER∼800 Ω cm2) with good expression of tight
junction proteins claudin-5, occludin and ZO-1, and shows
expression of functional BBB transporters (P-glycoprotein,
breast cancer-resistance protein), receptors (interleukin-1
receptor) and enzymes (alkaline phosphatase) (Patabendige
et al., this issue; Skinner et al., 2009). The strengths of this
model are that it is relatively simple and straightforward to
generate compared to other published porcine BBB models
and is able to give high TEER reliability even without co-
culture with astrocytes. For certain specialised studies, BBB
features can be further upregulated by exposure to astrocytes
or astrocyte-conditioned medium (ACM). The model has been
validated in studies of basic functions of the BBB at the
cellular and molecular level, screening of drug entry into
brain for pharmaceutical purposes, and examination of
mechanism(s) for CNS entry of ‘biologicals’ (large organic
molecules) (Patabendige et al., this issue; Skinner et al., 2009).
It is highly suitable for a range of further studies including
cell:cell interaction.
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method for isolation of porcine brain microvessels and
culture of PBECs to establish a BBB model with high TEER.
We present two variants of the model: (1) PBECs in mono-
culture—the simplest variant of the model which gives high
TEER reliably (Fig. 1 summarises the method), and (2) PBECs
co-cultured with rat astrocytes, useful when expression of a
speciﬁc receptor, transporter, or vesicular transport system
needs to be increased/induced using astrocytic factors. We
have given a short history of the model, to show its devel-
opment and reﬁnement in three phases spanning over more
than a decade of research. Optimal growing conditions for
generating well-differentiated PBEC monolayers on plastic
and on Transwell inserts for functional studies including
examination of transendothelial solute ﬂux were tested using
different extracellular matrix coatings (type I collagen or rat
tail collagen, with or without ﬁbronectin), and elevation of
intracellular cAMP (cAMPi). Both matrix composition and
cAMPi are known to affect the state of differentiation in a
variety of cell types (Rubin et al., 1991; Tilling et al., 1998). To
further encourage development of a BBB phenotype, we
tested addition of hydrocortisone to improve tightness of
the monolayer (Hoheisel et al., 1998), puromycin during early
stages of growth to kill contaminating pericytes (Perrière
et al., 2005) and addition of astrocyte factors (in ACM, or byFig. 1 – Flow chart showing porcine brain endothelial cell culture
dissection of pig brains to growth of porcine brain endothelialco-culturing with astrocytes in a non-contact model) (Gaillard
et al., 2001; Haseloff et al., 2005; Wolburg et al., 1994).2. Results
2.1. Isolation of brain capillary endothelial cells
A homogeneous and smaller diameter vessel fraction was
collected from the ﬁner ﬁlters (60 mm mesh) than from the
coarser ﬁlters (150 mm mesh). Furthermore, TEER of PBEC mono-
layers cultured from the 60 mm fraction was higher, consistent
with the 60 mm fraction being derived from purer capillaries (60s:
625721Ω cm2, n¼6, cf. 150s: 237710Ω cm2, n¼6).
2.2. Characterisation
Characterisation of the brain endothelial cell monolayers
produced by this method (Patabendige et al., this issue) and
the co-culture variant (Skinner et al., 2009) are published
elsewhere. By a range of morphological, immunocytochem-
ical and functional criteria, the cells reproduce well in vivo
endothelial and BBB features, from expression of endothelial
markers, to organisation of tight junction proteins, and exp-
ression of typical BBB enzymes and transport systems. Theymethod (mono-culture variant). Sequence of procedure from
cells for experiments.
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molecular function of the BBB (in preparation).
2.3. Morphology, assessment of barrier integrity and
reproducibility
TEER is one of the best measures of the barrier function of an
in vitro BBB model, and has been used throughout the optimi-
sation of this method and applications of the resulting model
variants.
2.3.1. Initial development of method
The initial development of this method was carried out at Eisai
laboratories (London), by modifying a protocol for bovine brain
(Rubin et al., 1991). A primary aim was to keep the dissection
and capillary isolation steps as short as possible, expecting that
this would favour endothelial cell yield and viability. Hence
although larger pieces of white matter and all of the meninges
were removed in dissection, no ﬁne cleaning to pick off small
pieces of white matter was used. Capillary fragments were
cultured in 50% ACM (with 10% bovine plasma-derived serum,
BPDS):50% Dulbecco's modiﬁed Eagles medium (DMEM with
10% BPDS, 1% glutamine and 1% penicillin/streptomycin) and
125 mg/mL heparin. The cells took 4–5 days to reach 50–80%
conﬂuence and had a few contaminating cells, likely pericytes
and connective tissue cells that labelled with antibodies against
smooth muscle actin (Fig. 2). To generate a robust TEER, PBECs
were established on Transwell ﬁlters in the growth medium
(N2 deﬁned medium with 10 mg/mL transferrin, 100 mM putres-
cine, 0.3 nM sodium selenite, 5 mg/mL insulin and 20 nM pro-
gesterone) containing 50% ACM and treated with agents that
elevated cAMPi. Using this method, TEER in the range of 400–
600 Ω cm2 could be obtained (Schulze et al., 1997), a 1.3–2.4-fold
increase in TEER compared to cultures in ACM/N2 alone. To
further increase TEER, passaged PBECs were also grown on
Transwell ﬁlters in the growth medium containing 50% ACM in
human endothelial serum-free medium (hESFM, Gibco), a for-
mulation that contains hydrocortisone (Battista and Soderland,
1995; Gorﬁen et al., 1993). This caused a 2.5–3.5-fold increase in
TEER compared to the cells in 50% ACM/N2 alone.
2.3.2. Changes introduced to improve the quality of PBECs
Experience with a number of primary brain endothelial cell
culture models in our groups and elsewhere has indicated that
thorough removal of meninges and white matter, and treatment
to kill pericytes lead to improvements in purity and yield, and in
growth and barrier characteristics. Also, since the composition of
Gibco hESFM used in the initial method is not reported in the
literature, it appeared worthwhile to test simpler growth media
(DMEM) supplemented with hydrocortisone.
2.3.3. Inﬂuence of special treatments on barrier integrity
To optimise the isolation of brain microvessels, special attention
was given during initial isolation to removing all meninges
(including inside sulci) and most of white matter, and this led
to increased culture purity, with fewer contaminating cells
growing out from the isolated vessel fragments. The extra time
taken over the preparation, while slightly reducing yield, resulted
in purer cultures. To reduce the ‘edge effects’ caused by leak of
current around the edges of the monolayer at the circumferenceof the insert, larger inserts were used (12mm diameter, hence
smaller circumference:surface area ratio). In the ﬁrst series of
experiments (Fig. 3A), TEER of cells grown in normal PBEC
medium peaked at ∼100Ω cm2 at 2 days and then declined.
A similar pattern was seen in cells grown in PBEC medium or
medium without serum, but supplementation at 48 h by adding
hydrocortisone and increasing cAMPi increased peak resistance
to ∼400Ω cm2 in serum-free medium and to ∼530Ω cm2 in
serum-containingmedium; in supplementedmedium, especially
medium containing serum, the high resistance phase lasted
longer than in normal PBEC medium (Fig. 3B). Puromycin treat-
ment was introduced to kill pericytes (Perrière et al., 2005).
Addition of 4 mg/mL puromycin in the ﬁrst three days of growth
led to a signiﬁcant further improvement in purity of the PBEC
culture and a signiﬁcant increase in TEER. In addition, using
BPDS rather than foetal calf serum (FCS) in the culture medium
also increased TEER (Fig. 4).
2.3.4. Reproducibility and reliability
To reduce variability of TEER observed with the STX2 chopstick
electrodes, the WPI Endohm chamber system was used, with
large concentric plate electrodes above and below the insert.
TEER of 485–1300Ω cm2 (Fig. 5) was typically obtained (mean
TEER¼789718Ω cm2; n¼91 inserts), with good reproducibility
between vials (Fig. 6) and batches. Furthermore, the correspond-
ing TEER and Papp values from each batch conﬁrm the reliability
of the model, showing high TEER correlated with low [14C]suc-
rose permeability (Fig. 7). Mean Papp for [
14C]sucrose was 5.77
0.710–6 cm/s (n¼7 experiments, 3 inserts each). Further func-
tional characterisation of this phase of the porcine BBB model is
described in detail elsewhere (Patabendige et al., this issue).
2.3.5. Co-culture variant
Pericyte contamination was reduced by differential trypsini-
sation during passaging the cells before seeding onto inserts
and DMEM was used with ACM (i.e. DMEM/ACM). Conﬂuent
monocultures of PBECs had an elongated cobblestone-shaped
morphology, although not generally so clearly spindle-
shaped as reported for rat and bovine brain endothelial cell
cultures. However, co-culture of PBECs with astrocytes
resulted in a more marked spindle-shaped morphology
(Fig. 8). With medium supplemented at 48 h, TEER measured
at 72 h was 595724 Ω cm2 in mono-cultured cells, and
779719 Ω cm2 in cells co-cultured with astrocytes in the
bottom of the well (Fig. 9). The apparent permeability (Papp)
to [14C]mannitol measured across the same inserts was in the
range 0.1–2.610−5 cm/s (Fig. 10), and showed an inverse
relation to the TEER.3. Discussion
3.1. Isolation of microvessel rather than large vessel
endothelium
The careful removal of meninges, including its invaginating
folds into sulci, was designed to remove the large surface
vessels, including many of the penetrating arterioles which
run perpendicularly into the brain cortex (Dacey and Duling,
Fig. 2 – Porcine microvessel explants. Phase contrast micrograph of PBECs (a) 9 h, and (b) 3 days in culture. In 9 h the capillary
fragments have attached to the collagen/fibronectin substrate and cell processes can be seen emerging from the explant.
After longer in culture endothelial cells have migrated away from the explant site. To facilitate labelling, porcine
microvessels were plated directly on to Transwell inserts and were grown for 5 days (c and d). The monolayer of PBECs,
labelled with antibody to the adherens junction catenins p100/p120 (c), is continuous over the top of some cells that do not
express endothelial cell markers, these cells label with antibodies to smooth muscle-specific actin (d). Scale bar: 100 lm in (a)
and (b); 50 lm in (c) and (d).
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contamination by leptomeningeal cells with ﬁbroblast-like
properties, but also by arterial and arteriolar smooth muscle
cells, which tend to grow more rapidly than endothelial cells
in culture. The two-stage ﬁltration is designed to retain vessel
fragments, allowing isolated cells including most glial cells to
pass through. Examination of the material collected from the
coarser and ﬁner ﬁlters (150 mm and 60 mmmesh respectively)
shows that the 150 mm ﬁlters retain a less pure (and generally
larger diameter) vessel fraction than the 60 mm ﬁlters; the
latter generate a more homogeneous and higher TEER mono-
layer consistent with it being derived from relatively pure
capillary endothelium. Isolation of predominantly capillary
rather than arteriolar or venular microvessels is important as
there are several phenotypic and functional differences
between the endothelial cells of these different segments of
the microvasculature. In particular, compared with arteriolar
or venular endothelium, cerebral capillary endothelium has
more a more complex and complete pattern of tight junction
strands in freeze-fracture images (Nagy et al., 1984) consis-
tent with tighter tight junctions (Wolburg and Lippoldt, 2002),
high expression of solute transporters including efﬂux trans-
porters (Ge et al., 2005; Macdonald et al., 2010; Saubamea
et al., 2012), and of certain receptors involved in transcytosis
such as transferrin receptor (Ge et al., 2005). Arteriolar
endothelium shows higher expression of certain enzymes
including 5′-nucleotidase, Mg2+-ATPase and Na+-K+-ATPase
than capillary or venular endothelium (Vorbrodt et al., 1982,1988), and signiﬁcant absence of P-glycoprotein (Saubamea
et al., 2012); bidirectional transcytosis of horseradish perox-
idase (creating a local ‘leak’) has been reported in certain
brain arterioles but not in capillaries or venules (Westergaard
and Brightman, 1973; van Deurs, 1977). The post-capillary
venule segment is specialised as a site regulating adhe-
sion and trafﬁc of leucocytes into the perivascular space
(Bechmann et al., 2007; Owens et al., 2008; Muldoon et al.,
2013), shows higher expression of genes involved in inﬂam-
mation-related tasks (Macdonald et al., 2010), and is more
affected in inﬂammatory conditions than capillary endothe-
lium (Paul et al., 2013). Given the much greater area of the
cerebral microvascular surface contributed by capillary
endothelium compared with arteriolar or venular endothe-
lium (Abbott et al., 2006), preparation of cultures from
relatively pure capillary fragments should give the tightest
monolayers reﬂecting most closely the transporting endothe-
lium of the BBB.
3.2. Pericyte contamination
In cultures of rat brain endothelial cells, contaminating
pericytes frequently grow in the same plane as the endothe-
lial cells, and are typically surrounded by a cell-free zone
leading to holes in the endothelial monolayer (Abbott et al.,
1992; Parkinson and Hacking, 2005). By contrast, in the
porcine model the pericytes generally grow below the endo
thelial layer, close to or directly on top of the extracellular
Fig. 3 – Effect of supplements and serum on TEER in
monocultured porcine in vitro BBB model (without
astrocytes). P.1 PBECs were seeded on Transwell inserts in
12-well plates with normal medium containing serum and
the TEER wasmeasured every day for a week (A). In the next
series of experiments (B), PBECs were seeded on Transwell
inserts, and after 48 h (arrow) the medium was changed to
either normal PBEC medium containing serum (▼), PBEC
mediumminus serum (’), PBEC medium plus supplements
(CPT-cAMP, RO 20-1724 and hydrocortisone) (▲) or PBEC
medium plus supplements minus serum (♦). Data are
means7SEM (n¼4 Transwell inserts); p values are shown
for differences from the condition in normal medium, with
serum but without supplements (po0.01, po0.05; two
way ANOVA, followed by Bonferroni post-hoc test).
Fig. 4 – TEER measurements of P.1 PBECs grown using
different culture conditions. Cells were grown on 12mm
diameter ‘Transwell Clear’ filter inserts (0.4 μm pore size).
Control cells were grown in medium containing foetal calf
serum (FCS) without puromycin. Test cells were treated with
puromycin and were grown in culture medium containing
either FCS or bovine plasma-derived serum (BPDS). Values
have been corrected for resistance of a ‘blank’ cell-free
insert and are mean7SEM (n¼3 inserts). Statistical
significance was calculated using Student’s t-test (**po0.01;
***po0.001 compared to control).
b r a i n r e s e a r c h 1 5 2 1 ( 2 0 1 3 ) 1 6 – 3 0 21matrix (see Fig. 2) (Abbott et al., 1997). Hence high TEER can be
achieved even in the presence of a small percentage of
pericyte contaminants, since they do not necessarily cause
holes in the PBEC monolayer. However, PBECs growing on top
of pericytes show a slightly altered morphology, with broader
cells and irregular cell borders, compared to the elongated
spindle-shaped morphology of PBECs without pericyte
growth underneath (Fig. 2). In our experience, treatments to
remove pericytes as thoroughly as possible gave the tightest
monolayers. Puromycin, substrate of the brain drug efﬂux
transporter P-glycoprotein (P-gp) was used to reduce peri-
cytes contamination. Brain endothelial cells have stronger
expression of P-gp than pericytes, so can restrict cellular
uptake of the cytotoxic puromycin, while pericytes are more
vulnerable, tend to be killed by puromycin treatment (Perrièreet al., 2005). Proliferating endothelial cells release platelet-
derived growth factor (PDGF) that attracts pericytes, and can
lead to vessel (tube) formation and release of vascular endo-
thelial growth factor (VEGF) through interactions between
endothelial cells and pericytes (von Tell et al., 2006). VEGF
increases the permeability of the BBB (Dobrogowska et al.,
1998). Therefore, reducing the number of pericytes in the
culture favours monolayers rather than vessel formation and
leads to uniform monolayers of contact-inhibited endothelial
cells with low permeability.
3.3. Supplementation to increase barrier integrity
Supplementation with treatments to elevate cAMPi was
based on a successful protocol for bovine brain endothelial
cells (Rubin et al., 1991), and was consistently found to give
tighter monolayers in the PBEC model. The treatment of
choice now also includes supplementation with hydrocorti-
sone, found to sustain tighter layers in many brain endothe-
lial models (Förster et al., 2008; Hoheisel et al., 1998). In a
porcine brain endothelial model developed by Galla and
co-workers (Franke et al., 1999, 2000), the presence of ox
serum in the medium was found to reduce TEER (Nitz et al.,
2003), attributed to the presence of permeabilising factors
including lysophosphatidic acid (LPA) and VEGF. Growth fac-
tors such as PDGF and VEGF can increase BBB permeability by
disrupting tight junctions and stimulating angiogenesis
(Dobrogowska et al., 1998; Harhaj et al., 2002; Wang et al.,
1996, 2001). To induce better barrier properties, some plasma-
derived sera are treated with charcoal to reduce the
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Fig. 5 – Histogram of TEER data from different PBEC cultures. Puromycin-treated PBECs were passaged and were grown on
Transwell inserts for 2 days. Cells were treated with supplements (CPT-cAMP, RO 20-1724 and hydrocortisone) for 24 h and
the TEER measured (13 vials from two batches isolated from 12 pig brains). TEER was measured in 91 inserts in 24
independent experiments. TEER of a ‘blank’ cell-free insert has been subtracted from all values.
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Fig. 6 – Reproducibility of TEER within a batch of PBECs; P.1
PBECs from different vials. Puromycin-treated PBECs from
three vials from the same batch were passaged and grown
on 12 mm diameter Transwell Clear filter inserts (0.4 lm
pore size) for 2 days. Cells were treated with supplements
(CPT-cAMP, RO-20-1724 and hydrocortisone) for 24 h and
TEER measured. TEER of a ‘blank’ cell-free insert has been
subtracted from all values. Mean7SEM (n¼3).
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Fig. 7 – TEER and sucrose permeability of P.1 PBECs from two
batches. Puromycin-treated PBECs from two batches were
passaged and were grown on Transwell inserts for 2 days.
Cells were treated with supplements (CPT-cAMP, RO 20-1724
and hydrocortisone) for 24 h then used for experiments
(mean7SEM, n¼3 inserts per batch). For TEER, the relevant
value of a ‘blank’ cell-free insert has been subtracted from
all data. TEER is represented by the bars (left y-axis) and
respective monolayer permeability to [14C]sucrose is shown
by the points (right y-axis).
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charcoal-stripping of serum can lead to removal/reduction
of other biologically important factors such as hormones,
vitamins, enzymes and electrolytes (Cao et al., 2009). In the
present model, we chose to use BPDS, which being derived
from adult bovine plasma, is collected with generally less
stress to the donor, and contains lower concentrations of
growth factors (e.g. PDGF, VEGF) and other vasoactive/prolif-
erative factors than foetal or neonatal calf serum (Abbott
et al., 1992). BPDS increased the TEER of the brain endothelialcells compared with serum-free medium, consistent with
observations that serum proteins stabilise capillary endothe-
lial permeability, by cross-linking the glycocalyx and possibly
also the exposed proteins of the outer zones of the junctional
complexes (Curry and Michel, 1980). Where experiments need
Fig. 8 – Morphology of P.1 PBECs stained for endothelial cells marker, IB4. P.1 PBECs were seeded on Transwell inserts treated
with supplements (cAMP, RO20-1724 and hydrocortisone) and cultured in the absence (A) or presence of astrocytes (B) in the
bottom of the well. P.1 PBECs were then treated with IB4-FITC for 30 min, fixed, and mounted for visualisation. Scale bar;
25 lm.
Fig. 9 – Effect of astrocytes on TEER of porcine in vitro BBB
model. P.1 PBECs were seeded on Transwell inserts in
12-well plates with (P.1 PBECs+AS) or without (P.1 PBECs)
astrocytes (AS) in the bottom of the well. After 48 h,
supplements (CPT-cAMP, RO 20-1724 and hydrocortisone)
were added and TEER was measured at 72 h. Data are
mean7SEM; PBEC, n¼6 and PBEC +As, n¼33 Transwell
inserts. Statistical significance was calculated using
Student’s t-test (**po0.01 vs. control PBEC alone).
Fig. 10 – Mannitol permeability of PBEC monolayers as a
function of their TEER. P.1 PBECs were seeded on Transwell
inserts treated with supplements (CPT-cAMP, RO 20-1724
and hydrocortisone) and cultured in the presence of
astrocytes in the bottom of the well. TEER was measured
prior to [14C]mannitol permeability experiments. Each point
represents one Transwell insert.
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withstand serum removal for 24 h before experiments.3.4. Comparison of variants
Both mono-culture (Patabendige et al., this issue) and co-
culture (Skinner et al., 2009) of the PBEC model variants
are capable of giving monolayers of TEER 4400 Ω cm2. For
many applications examining the BBB ﬂux of drug-like
molecules and other small solutes, this is sufﬁcient to give
good resolution between transcellular and paracellular ﬂux
(Gaillard and de Boer, 2000). The relationship between Papp
mannitol and TEER observed in our model (Fig. 10) is similar
to that reported by Gaillard and de Boer (2000) using two
other paracellular permeability markers, sodium ﬂuorescein
and 4 kDa FITC-dextran; in our model, Papp was relatively
independent of TEER when TEER was4200 Ω cm2. As TEER is
inversely related to the small ion conductance (and hencepermeability) of the monolayer, TEER recorded at the start of
an experiment is a good measure of the ‘basal’ paracellular
permeability of the cells, as reference for studies e.g. with
drugs which may themselves alter permeability. For leakier
monolayers, the TEER can be used to derive a corrected
permeability coefﬁcient for a drug from the measured Papp
(Gaillard and de Boer, 2000); however, when TEER is high
enough for Papp to be relatively independent of TEER, the
measured Papp is sufﬁcient without correction, and suitable
for comparisons between laboratories.
There is an extensive literature showing that exposure to
astrocytes or astrocyte-conditioned medium increases the
expression of several BBB features in brain endothelial
monolayers (Dehouck et al., 1990; Pottiez et al., 2011) so using
the astrocyte co-culture or ACM variants of the method may
be required for some applications (Gaillard et al., 2001)
including those where vesicular-mediated transcytosis of
large molecules is involved (Candela et al., 2008; Demeule
et al., 2002; Skinner et al., 2009). However, our experience has
been that the state of differentiation of the endothelium also
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mentation with hydrocortisone plus elevation of cAMPi,
combined with growth on extracellular matrix mimicking
the native brain endothelial/astrocyte basement membrane,
without addition of astrocyte-derived inﬂuence, may be
sufﬁcient for many applications.
3.5. Comparison with PBEC models in the literature
Several promising PBEC models have been introduced over
the last decade (Cohen-Kashi Malina et al., 2009; Franke et al.,
2000; Smith et al., 2007; Zhang et al., 2006). However, several
things drove our development of an alternative to published
methods. At the start of this process (early 1990s) there was
no reliable published method for generating porcine brain
endothelial cells. Since then, several methods have been
described, but intra-batch and batch-to-batch variation was
still a problem with many of them (Franke et al., 2000; Zhang
et al., 2006). There was some variability in the effects of
adding serum, reported to either increase or decrease perme-
ability (Nitz et al., 2003), and it was not always clear whether
astrocytic inﬂuence was necessary. While astrocytes were not
required to generate a high TEER in the PBEC model described
by Franke et al. (2000), others have reported that astrocytic
inﬂuence is necessary to produce a practical model (Cohen-
Kashi Malina et al., 2009; Smith et al., 2007). In general, where
a brain endothelial cell culture model achieves a high TEER
without astrocytic inﬂuence (Franke et al., 2000; Lohmann
et al., 2002; Patabendige et al., this issue; Zhang et al., 2006),
functional expression of small solute transporters (SLCs) and
efﬂux transporters is found to be sufﬁcient to allow use of the
monocultures for drug permeability assay. For leakier mod-
els, co-culture with astrocytes (Cohen-Kashi Malina et al.,
2009; 2012; Kido et al., 2002) or C6 glioma cells, or exposure to
glial-conditioned medium (Smith et al., 2007) may be neces-
sary to tighten the barrier and improve expression of other
BBB properties such as enzymes and transporters, to produce
functional assay systems. For certain specialised features of
the brain endothelium such as receptor-mediated transcyto-
sis, astrocyte co-culture may be necessary even with tighter
monolayers (Skinner et al., 2009).
A detailed comparison of the methods and barrier char-
acteristics of the main PBECs models in comparison to our
model is given in Patabendige et al. (this issue). The strengths
of the present method are that it is relatively simple, invol-
ving fewer preparative steps, and that it gives a high yield.
With this method (Patabendige et al., this issue), reliably tight
brain endothelial cell monolayers can be grown on inserts
without astrocyte inﬂuence, and if needed, serum can be
removed for the last 24 h to provide suitable starting condi-
tions for experiments, without signiﬁcantly compromising
tightness. The alternative co-culture variant of this method
described provides considerable ﬂexibility for experimental
design, depending on the application.
The ultimate goal for most BBB researchers is to be able to
study the human BBB. However, the difﬁculties associated
with developing robust and realistic in vitro human BBB
models have led to the use of animal models (Patabendige,
2012). A porcine BBB model is a good alternative as the
biology of the pig is closer than that of other laboratoryanimals to the biology of the human (Walters et al., 2011).
The PBEC model presented in this paper is one of the best BBB
models giving high TEER. However, as with all BBB models,
there are some limitations. Strict adherence to the experi-
mental procedure is required to produce high yields of pure
PBEC cultures and to minimise variation between batches.
Only limited in vivo data is available for porcine models
compared to rodent models; however, with the increased
use of transgenic and miniature pigs this will improve in
future. Availability of good porcine primers and antibodies is
currently an issue, but this also will improve with the recent
publication of a high-quality draft pig genome sequence
(Groenen et al., 2012). Further examination of expression
and function of transporters and receptors on the PBEC model
is currently under way.
In summary, this method combines simplicity and repro-
ducibility with optimum cell yield and purity, making the
resulting PBEC model robust, reliable and ﬂexible, with good
preservation of BBB features, suitable for a range of appli-
cations.4. Experimental procedure
4.1. Time required
8 h isolation of brain capillaries and freezing (from 6 pig
brains)
3 days cell culture
1 h passaging of cells onto Transwells ﬁlter inserts
2–3 days cell culture to conﬂuence
15 min medium exchange (‘switch medium’)
24 h later: ready for experiments
The total time required from cell preparation to having
suitable cell cultures for mechanistic and transport stu-
dies is 8 days, but the cells stay in well-differentiated state
for up to 4 days after this.
4.2. Materials
Culture medium L-15 Leibovitz (L-15); medium 199 (M199);
DMEM; Penicillin (10,000 U/mL)/Streptomycin (10 mg/mL)
(P/S); Glutamine (2 mM stock soln); Heparin; Puromycin;
cell permeant cAMP analogue, CPT-cAMP; Hydrocortisone;
Trypsin-EDTA for endothelial cells; Hanks’ balanced salt
solution (HBSS) without (w/o) Ca2+,Mg2+; FCS; poly-D-lysine;
human ﬁbronectin; dimethyl sulfoxide (DMSO); all from
Sigma. Type IV phosphodiesterase inhibitor, RO 20-1724 from
Calbiochem/Merck. Enzymes from Lorne Laboratories Lim-
ited, UK. Collagenase, Trypsin, DNase I. Minimal essential
medium (MEM+HEPES) from MP Biomedicals. Phosphate
buffered saline (PBS) with Ca2+ and Mg2+ from Cambrex Bio
Science. BPDS from First Link UK. Nylon meshes (60 mm and
150 mm pore size) from Plastok Associates, UK. Rat tail
collagen type I from Becton Dickinson. Tissue culture plastics
(ﬂasks, plates, Petri dishes). Filter inserts: Costar ‘Transwell
Clear’ 12-well tissue-culture-treated sterile polyester mem-
brane, 0.4 mm pore, 12 mm membrane, pre-loaded on cluster
plates. [14C]sucrose (0.15 mCi/mL ﬁnal concentration, speciﬁc
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concentration, speciﬁc activity 56 mCi/mmol) from GE
Healthcare. Anti-smooth muscle-speciﬁc actin (monoclonal-
mouse) from Dako Ltd.; monoclonal antibody against p100/
120 from Transduction Laboratories (now BD Biosciences).
Anti-mouse secondary antibodies were from Jackson Immu-
noresearch Laboratories Inc. and nuclear stain Hoechst 33342
was from Sigma. FITC-labelled IB4 was from Gibco, Paisley,
UK and ProLong Mounting Medium containing Dapi was from
Invitrogen, UK. Lab-made rat-tail collagen (Strom and
Michalopoulos, 1982). All other chemicals not quoted speci-
ﬁcally were obtained from commercial sources at the highest
quality available.4.3. Laboratory equipment Refrigerated centrifuge
 Dounce glass homogeniser (40 mL, with loose and tight
pestle) Dissecting instruments set: ﬁne forceps (for ﬁne dissec-
tion, removal of meninges), curved forceps (for separation
of white matter from grey matter), coarse forceps (‘rat-
toothed’), scalpel Nalgene reusable ﬁlter holder unit for 47 mm diameter
membranes (500 mL receiver) from Fisher Scientiﬁc Three clean glass beakers
 Sterile plastics: 1 L containers, 15 cm Petri dishes, 50 mL
centrifuge tubes, 50 mL syringe, T75 and T175 ﬂasks, sin-
gle-wrapped tissue culture pipettes (10 mL, 25 mL) 200 mL glass bottle for preparation of ‘Digest Mix’ stock
 60 mm and 150 mm nylon mesh, cut slightly larger than the
size of ﬁlter unit; gauze and paper towels Measurement of TEER: EVOM2 voltohmeter with ENDOHM-
12 electrode chamber, and/or STX2 chopstick electrodes,
both from World Precision Instruments, USA Automatic pipettes+tips (e.g. Gilson)
4.4. Composition of solutions and media Transport solution for transferring brains to laboratory. L15
medium with added penicillin (100 U/mL), streptomycin
(100 mg/mL) (Pen/Strep). Washing and dissection solution: HEPES buffered MEM con-
taining 10% FCS and 1% P/S (% by volume). Digest Mix: Enzymes in M199 medium with FCS and P/S. Weigh
out 188mg collagenase (223 U/mg), 86mg trypsin (211 U/mg),
10.9 mg DNase I (2108 U/mg). Add 178mL of M199 and ﬁlter
sterilise into an autoclaved 200mL glass bottle. Then add
20mL FCS and 2mL P/S. Aliquot into centrifuge tubes and
freeze at −20 1C. Freezing mix: Resuspend vessel fragments in 10% DMSO in
FCS and aliquot to cryovials (1 mL each), bring slowly to
−80 1C (use a cryo freezing container to achieve −1 1C/min
cooling rate; place vials in the container and place it in
−80 1C freezer for 24 h), then store vials in liquid nitrogen. Basic growth medium: DMEM, 10% BPDS, 1% P/S, 1% Gluta-
mine and 125 μg/mL heparin. Pass through 0.22 mm ﬁlter
before use. Switch (differentiation) medium: Once cells are growing well on
inserts, change growth medium to serum-free switch med-
ium containing DMEM, 1% P/S, 1% Glutamine, 125 μg/mL
heparin and 550 nM hydrocortisone. Then treat cells with
250 mm CPT-cAMP and 17.5 mm RO 20-1724 (see below for
timings).
4.5. Animals and yield
The culture of each batch of cells starts with six pig brains
(from abattoir), and generates 12 cryovials each of ‘60s’ and
‘150s’, indicating the ﬁlter mesh size used for their isolation.
One vial is sufﬁcient for two T75 ﬂasks and cells from two T75
ﬂasks are enough for 18–24 Transwell 12 mm diameter inserts
(1105 cells/insert). Hence six brains yield ∼2420¼480
Transwell inserts with conﬂuent cells.
4.6. Preparations (day before isolation) Sterilise dissecting instruments, glass beakers, homogeni-
ser, ﬁlter unit, six circles each of 60 mm and 150 mm nylon
mesh, gauze and sterile 1 L containers Prepare a solution of L-15 medium with 1% P/S (L-15+)
 Prepare a solution of PBS with Ca2+ and Mg2+ with 1%
P/S (PBS+) Prepare a solution of MEM/HEPES medium with 10% FCS
and 1% P/S (Mem/HEPES+) Sterile disposables: Scalpel, cell scrapers, 50 mL syringes,
single-wrapped tissue culture pipettes, Petri dishes, cen-
trifuge tubes, labelled cryovials, T75 and T175 ﬂasks
4.7. Detailed experimental procedure
4.7.1. Isolation of brain capillaries1. Collect brains from abattoir: Acquire 12 fresh porcine brain
hemispheres from the abattoir. Wash each hemisphere
brieﬂy in L-15+ and transport brains to lab in three sterile
1-litre tubs containing L-15+ on ice.2. Wash brain: Pour a little PBS+ into a beaker. Remove one
hemisphere from the container and wash thoroughly
in PBS+.3. Remove meninges: Place some gauze in a Petri dish. Place one
hemisphere in your hand directly above the Petri dish. Using
ﬁne forceps carefully remove the meninges. Make sure to
remove the meninges inside the grooves (sulci). Wash again
and place in a new beaker containing fresh PBS+. Spray
hands with 70% ethanol. Repeat for all the hemispheres.4. Remove white matter: Place a cleaned hemisphere in your
hand. Remove the white matter (cut off large chunks
where possible, and use curved forceps to pinch off small
whole sections of white matter). Place grey matter in a
beaker containing MEM/HEPES+. Repeat for all hem-
ispheres.5. Cut into small pieces: Remove the MEM/HEPES+ in beaker
and replace with fresh MEM/HEPES+. Use a scalpel to
chop the brain into pieces of ∼1 cm3.6. Extrude brain material through syringe: Half ﬁll a 50 mL
syringe with the brain matter (use forceps to transfer)
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HEPES+.7. Homogenise: Pour 15 mL of brain extract from the T75 into
the homogeniser. Top up with MEM/HEPES+ to just below
the wider part of the homogeniser (total volume should
be about 40 mL). Homogenise very gently up and down for
15 strokes with the loose pestle and then 15 strokes with
the tight pestle. Pour homogenate into a clean T175.
Continue until all tissue has been homogenised, pool
homogenate (1000–1200 mL).8. First ﬁltration using 150 mm mesh: Filter about 200 mL of the
homogenate through a sterile 150 μm mesh. Rinse the
ﬁlter with about 40 mL of MEM/HEPES+. Remove ﬁlter
from the ﬁlter unit and place the ﬁlter in a 15 cm Petri
dish containing 80 mL of digest mix. Continue with
further ﬁlters, adding them to the dish. Incubate ﬁlters
for one hour at 37 1C on a shaker or rocker. This will make
the ‘150 s’ sample.9. Second ﬁltration using 60 mm mesh: Take ﬁltrate from step 8
and ﬁlter again, this time through 60 μm mesh (200 mL
per ﬁlter). Again rinse and remove each ﬁlter and add to a
second Petri dish containing 80 mL of digest mix. Incu-
bate for one hour at 37 1C on an orbital shaker or rocker.
This will make the ‘60s’ sample.10. Harvest microvessels from ﬁlters, keep 150s and 60s separate:
Collect the capillaries bound to the 150 mm ﬁlters using a
pipette. Remove the digest mix and place into two 50 mL
centrifuge tubes and spin down for 5 min at 240g at 4 1C.
Repeat for 60 mm ﬁlters, and from this point on keep the
resulting sample separate from the ‘150s’. These frac-
tions generally result in different qualities of endothelial
cultures—cells derived from capillaries caught on the
60 mm ﬁlters usually having fewer contaminating peri-
cytes.11. Triturate microvessel fractions: Aspirate off the supernatant
from the 150s and resuspend pellet in 10 mL of MEM/
HEPES+. Triturate suspension. Add 20 mL of MEM/HEPES+
and triturate up and down. Centrifuge again for 5 min at
240g at 4 1C. Repeat for the 60s.12. Resuspend and spin again: Repeat step 11 (i.e. resuspend
each pellet in MEM/HEPES+ and spin again for 5 min at
240g at 4 1C).13. Transfer cells into freezing mix: If cells are not being used
immediately, resuspend each pellet (150 s and 60 s) in
10.8 mL of FCS and 1.2 mL DMSO. Pipette 1 mL aliquots
into labelled cryo-vials. Transfer the vials into the freezing
container and freeze at −80 1C overnight. Then store in
liquid nitrogen.4.7.2. Thawing and growth
Coat two T75 ﬂasks with lab-made rat tail collagen (300 mg/mL in
sterile water) for 2 h at RT. Remove collagen andwash twice with
HBSS and add ﬁbronectin (7.5 mg/mL in sterile water) and leave
for 2 h at RT. After two hours remove ﬁbronectin and wash twice
with HBSS. Alternatively, ﬂasks can be coated with rat-tail
collagen only for 3 h at 37 1C. Thaw one aliquot per two
collagen/ﬁbronectin-coated T75 ﬂasks. Thaw vials by immersing
the bottom half of the cryovial in a water bath (37 1C) for 2–3min,
swirling gently. Add the thawed aliquot to 16mL of basic growth
medium (containing 4 mg/mL puromycin) and pipette into ﬂasks.PBECs become ∼80% conﬂuent within 3 days and can be
passaged at this stage.4.7.3. Setting up PBEC mono-culture model on Transwell
ﬁlters
Rinse cells twice with HBSS without Ca2+, Mg2+. Add 2 mL of
trypsin-EDTA per ﬂask and put ﬂask back into the incubator
for 3–5 min and then continually observe under the micro-
scope. Shake the ﬂask to detach endothelial cells and tap
gently if necessary. When the majority of endothelial cells
have come off add 8 mL of basic growth medium (without
puromycin) and transfer the contents of the ﬂask to a
centrifuge tube. Spin the cells for 5 min at 380g. Resuspend
the pellet in 1 mL of medium, count cells and seed the
passaged PBECs onto Transwell inserts at 1.0105 cells/cm2.
Use basic growth medium without puromycin until P.1 PBECs
become 100% conﬂuent.4.7.4. Special treatments to induce differentiation (‘Switch’
medium)
P.1 PBECs become conﬂuent 2–3 days after passaging onto
inserts. When 100% conﬂuent, change the medium to serum-
free switch medium and treat with 250 mM CPT-cAMP and
17.5 mM RO 20-1724. P.1 PBECs are ready for experiments after
24 h of this treatment. 60s give the best endothelial cells
(uniform, derived from smaller vessels) and should be used
for Transwell experiments; TEER range: 400–1300 Ω cm2. 150s
can be used for immunostaining and RNA/protein isolations;
still give a high percentage of endothelial cells but are more
likely to be from larger vessels and therefore, may have more
contaminating cells. TEER range: 100–400 Ω cm2; can be
higher if grown for longer.4.8. Co-culture variant
4.8.1. Astrocyte isolation
Prepare primary cultures of rat astrocytes by the method
described by McCarthy and de Vellis (1980). In brief, dissect
out cortices from 0 to 2-day-old Sprague-Dawley rat pups,
remove meninges and dissociate through a nylon net. Collect
the ﬁltrate, centrifuge for 10 min at 200g and re-suspend the
pellet in 10 mL DMEM with 10% FCS and 1% P/S. Seed at
5105 cells/mL in poly-D-lysine coated T75 ﬂasks and incu-
bate for 5 days. Change the medium every 3 days until 100%
conﬂuent. Remove cell contaminants by shaking on an orbital
shaking system at 37 1C overnight. Dissociate astrocytes
using trypsin, centrifuge cells for 5 min at 200g and
re-suspend the pellet in DMEM with 10% FCS and 1% P/S.
Seed at 1105 cells/mL into poly-D-lysine coated-12-well
plates and culture for 10 days. Determine purity (over 95%)
by glial ﬁbrillary acidic protein expression.4.8.2. Astrocyte-conditioned medium
For collection of ACM, feed astrocyte cultures with
fresh DMEM containing 10% BPDS. After 48 h, ﬁlter the
conditioned medium through a 0.2 mm pore nitrocellulose
membrane to remove cell fragments, snap freeze in dry ice
and store at −80 1C.
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Add a thawed PBEC aliquot to 36 mL of basic growth medium
(without puromycin) and pipette into collagen/ﬁbronectin-
coated 6-well plates. After 4 h, change the medium to 50%
ACM, 50% basic growth medium. PBECs should be passaged
when ∼60–70% conﬂuent.
Rinse cells with PBS and then with warm EDTA/PBS. Add
trypsin and put plate back into the incubator for 2 min and
then continually observe under the microscope. The endothe-
lial cells are more sensitive to trypsin so will come off ﬁrst.
Shake the plate gently but do not tap; tapping will cause the
cells to be removed in sheets taking the pericytes with them.
When the majority of endothelial cells have come off,
transfer the contents of the plate to a centrifuge tube con-
taining 0.5 mL FCS. Spin the cells for 5 min at 240g. Resus-
pend the pellet in 1 mL of basic growth medium, count cells
and seed onto Transwell inserts at 8104 cells/insert. Trans-
fer the inserts to a 12-well plate containing conﬂuent rat
astrocytes. Change the medium to ‘Switch’ medium when
PBECs are 100% conﬂuent.
4.9. Assessing barrier integrity and reproducibility:
Measuring TEER and mannitol or sucrose permeability
4.9.1. TEER measurements
BBB integrity can be assessed non-invasively and in real time
by TEER measurement. TEER was recorded in an Endohm
chamber or with STX2 chopstick electrodes (co-culture var-
iant) connected to an EVOM resistance meter (World Preci-
sion Instruments, Sarasota, FL, USA). According to Ohm's law,
V¼ IR where V, voltage; I, current; R, resistance. Resistance is
inversely proportional to permeability (or conductance), and
reﬂects permeability to small ions carrying electrical current.
For Endohm, PBECs grown on Transwell inserts were placed
between the ﬂat plate silver–silver chloride electrodes. When
chopstick electrodes were used, they were placed at a uni-
form distance from the cells grown on the inserts. Control
resistance measurements from ‘blank’ cell-free inserts were
subtracted to calculate the resistance of the cell monolayer.
Resistance values were multiplied by the surface area of the
insert membrane to express results in Ω cm2.
4.9.2. Permeability studies
[14C]sucrose permeability studies were performed on cell mono-
layers with TEER4500 Ω cm2. Culture mediumwas aspirated off
the inserts and the inserts were transferred to 12-well plates
(placed in a shaker at 37 1C) containing 1.5 mL/well of assay
buffer (DMEM without phenol red, 25 mM HEPES and 0.1%
bovine serum albumin). 0.5 mL of assay buffer containing [14C]
sucrose (ﬁnal concentration: 0.15 mCi/mL was added to the ﬁrst
insert and then to other inserts at 10-s intervals. At t¼5min,
the inserts were transferred to the next well containing assay
buffer. This procedure was repeated for all inserts at t¼15min
and 30min. At the end of the experiment (t¼30min), samples
were taken from each insert (50 ml sample+150 ml of assay
buffer) and well (200 ml sample) to scintillation vials, 5 mL of
scintillation ﬂuid added, and vials counted in a scintillation
counter. For the co-culture variant, permeability studies were
performed using [14C]mannitol on cells grown to conﬂuence on
Transwell inserts with a minimum TEER of 250 Ω cm2. [14C]mannitol was added to the insert (ﬁnal concentration 3.6 μM).
Samples (100 μL) were taken from the well after 0, 1 and 3 h. The
samples were added to 1mL of scintillation ﬂuid and counted
in a scintillation counter.
Cleared volume was plotted as a function of time and the
slope was obtained by linear regression. The slope of the
clearance curve represents the PS product (permeability sur-
face area). Apparent permeability (Papp, cm/s) was calculated by
dividing the PS product by the surface area of the ﬁlter.
4.10. Immunocytochemistry and cell staining
4.10.1. Immunocytochemistry
Transwell inserts were ﬁxed in 4% paraformaldehyde for
10 min, washed in PBS, permeablised in 0.5% Triton-X-100
in PBS for 20 min then blocked for 30 min in 10% calf serum
with 0.1 M lysine and 0.3% Triton-X-100 in PBS. Primary
antibodies were added in blocking solution at 4 1C overnight.
Transwell inserts were then washed and secondary antibo-
dies added in blocking solution with added nuclear stain
Hoechst 33342 at 1 mg/mL for 1 h at room temperature.
4.10.2. Cell staining using FITC labelled IB4
Cells were cultured on Transwell inserts and FITC-labelled
IB4 (1:200 dilution) was added to the apical side for 30 min
in the dark. The cells were then washed with PBS, ﬁxed
with 4% paraformaldehyde and mounted using Pro-Long
Mounting Media containing Dapi. Images of the stained
cells were obtained using a ﬂuorescent microscope
attached to a digital camera.
4.11. Statistical analysis
Data are expressed as mean (7standard error of the mean,
SEM) and analysed and presented using GraphPad Prism.
Groups of two were analysed using Student's t-test, groups of
three or more were analysed using either one-way analysis of
variance (ANOVA) with a Dunnets post-hoc test or, if multiple
variables were involved, two-way ANOVA with Bonferroni
post-hoc test was applied. Values were considered to be
signiﬁcantly different when po0.05.Acknowledgments
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